2. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-11 (Cancelled)

Claim 12. (Withdrawn) A method of preparing a dendritic cell population comprising the steps of:

- (a) contacting hematopoietic stem or progenitor cells with flt3-ligand in an amount sufficient to generate a dendritic cell population;
- (b) transfecting the dendritic cells with a gene encoding an antigen; and
- (c) allowing the dendritic cells to process and express the antigen.

Claim 13. (Withdrawn) A method according to claim 12, further comprising contacting the hematopoietic stem or progenitor cells with a molecule selected from the group consisting of GM-CSF, IL-4, TNF- α , IL-3, c-kit ligand, fusions of GM-CSF and IL-3, CD40 ligand, and CD40 antibody.

Claim 14 (Cancelled)

Claim 15 (Currently amended) A method of preparing a dendritic cell population comprising the steps of:

- (a) contacting hematopoietic stem or progenitor cells with a growth factor or cytokine, wherein the growth factor or cytokine consists of flt3-ligand in an amount sufficient to generate a dendritic cell population;
- (b) exposing the dendritic cells to an antigen; and
- (c) allowing the dendritic cells to process and express the antigen. wherein flt3-ligand is the only colony stimulating factor or cytokine used in the method.

Claim 16 (Currently amended) The method according to claim 15, further comprising contacting the hematopoietic stem or progenitor cells with wherein the growth factor or cytokine consists of fl3-ligand and GM-CSF.

Claim 17 (Withdrawn) The method according to claim 12 wherein the flt3-ligand is a recombinant human flt3-ligand.

Appl. No. 09/699,923 Resp. to OA of November 26, 2003

Claim 18. (Withdrawn) The method according to claim 13 wherein the flt3-ligand is a recombinant human flt3-ligand.

Claim 19. (Withdrawn) The method according to claim 13 wherein the molecule is a recombinant human GM-CSF.

Claim 20. (Withdrawn) The method according to claim 13 wherein the molecule is CD40 ligand.

Claim 21. (Withdrawn) The method according to claim 13 wherein the molecule is c-kit ligand.

Claim 22. (Withdrawn) The method according to claim 13 wherein the molecule is $TNF-\alpha$.

Claim 23 (Previously presented) The method according to claim 15 wherein the flt3-ligand is human flt3-ligand.

Claim 24 (*Previously presented*) The method according to claim 16 wherein the flt3-ligand is human flt3-ligand.

Claim 25 (Previously presented) The method according to claim 16 wherein the GM-CSF is human GM-CSF.

Claim 26. (Withdrawn) The method according to claim 16 wherein the molecule is CD40 ligand.

Claim 27. (Withdrawn) The method according to claim 16 wherein the molecule is c-kit ligand.

Claim 28. (Withdrawn) The method according to claim 16 wherein the molecule is TNF- α .

Claim 29 (Currently amended) A method of preparing a dendritic cell population, the method comprising contacting in vitro hematopoietic stem or progenitor cells with a growth factor or cytokine, wherein the growth factor or cytokine consists of flt3-ligand in an amount sufficient to generate a dendritic cell

Appl. No. 09/699,923 Resp. to OA of November 26, 2003

population, thereby generating the dendritic cell population..., wherein flt3-ligand is the only colony stimulating factor or cytokine used in the method.

Claim 30 (Previously presented) The method of claim 29, wherein the hematopoietic stem or progenitor cells have been enriched for the CD34+ phenotype.

Claim 31 (Currently amended) The method of claim 29, further comprising contacting the dendritic cells with—wherein the growth factor or cytokine consists of fl3-ligand and GM-CSF.

Claim 32 (Previously presented) The method of claim 31, wherein the GM-CSF is human GM-CSF.

Claim 33. (Withdrawn) The method of claim 31, wherein the molecule is TNFa.

Claim 34. (Withdrawn) The method of claim 31, wherein the molecule is c-kit ligand.

Claim 35. (Withdrawn) The method of claim 31, wherein the molecule is CD40 ligand.

Claim 36 (Previously presented) The method according to claim 29 wherein the flt3-ligand is human flt3-ligand.